Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3000 participants.
Also called NCT06763744
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,000 participants
- Sponsor
- Registry
-
NCT06763744
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06763744. Randomized; no masking; primary purpose treatment. Start 2025-06-01 (anticipated); primary completion 2029-07-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR
- Acronym
- GUIDE-HBR
- Condition
- Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI (percutaneous coronary intervention))
- Condition
- High Bleeding Risk
- Intervention (Drug)
- P2Y12 antagonist monotherapy
- Intervention (Drug)
- clopidogrel + aspirin
- Lead sponsor
- Samsung Medical Center
Record details
- Record id
cardio:ct-nct06763744- Content hash
ed39e45cac120a9c79c14b5956a75ca50fa29d41263f37f51d81374d9a85b770